Skip to main content
British Journal of Cancer logoLink to British Journal of Cancer
. 2016 Oct 11;115(9):e16. doi: 10.1038/bjc.2016.342

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

Angus G Dalgleish, Justin Stebbing, Douglas J A Adamson, Seema Safia Arif, Paolo Bidoli, David Chang, Sue Cheeseman, Robert Diaz-Beveridge, Carlos Fernandez-Martos, Rob Glynne-Jones, Cristina Granetto, Bartomeu Massuti, Karen McAdam, Raymond McDermott, Andrés J Muñoz Martín, Demetris Papamichael, Roberto Pazo-Cid, Jose M Vieitez, Alberto Zaniboni, Kevin J Carroll, Shama Wagle, Andrew Gaya, Satvinder S Mudan
PMCID: PMC5117801  PMID: 27727233

Correction to: British Journal of Cancer (2016) 115, 789–796; doi:10.1038/bjc.2016.271

Upon publication of the above paper in the British Journal of Cancer, the authors identified an error in one of their affiliations. The authors would like to apologise for this mistake. The correct affiliation for Andrés J Muñoz Martín is ‘Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain.'


Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES